Carl Zeiss Meditec’s revenues for the first quarter of its 2020/21 financial year reached €368.9 million, down by 0.2 percent year-on-year in reported terms but up by 2.6 percent after adjustment of currency effects. The overall topline recovery was fueled by the good performance of the Ophthalmic Devices’ business unit which posted sales of €283.4 million, an increase of 8.2 percent on a neutral currency basis thanks to strong recurring revenues. Conversely, revenues in the Microsurgery segment dropped by 12.3 percent in adjusted terms to €85.5 million as the division’s business was slowed down by ongoing restrictions related to the pandemic. However, the company said that Microsurgery revenues would improve in the next months as the order backlog was now back to last year’s levels.

Carl Zeiss Meditec’s Ebit margin increased from 15.4 percent in Q1 2019/20 to 19.9 percent this year, due to lower selling and marketing expenses and an improved product mix in the Ophthalmic Devices unit. The division’s Ebit margin jumped by 8.5 percentage points in the quarter to 19.5 percent while the sales drop brought the Microsurgery unit’s Ebit margin down by 6 percentage points to 21.5 percent.